Prescription Medicine in Pregnancy: A Complete Clinical Guide

Why Prescription Medicine in Pregnancy Demands Special Consideration

Pregnancy changes almost every pharmacokinetic variable that governs drug behavior. Renal clearance rises by 40 to 65%, plasma volume expands by roughly 50%, and hepatic CYP enzyme activity shifts unpredictably across trimesters. A 2021 review in Clinical Pharmacokinetics documented that these changes require dose adjustments for at least 14 drug classes commonly used in obstetric care. Ignoring them produces either sub-therapeutic levels or toxicity.

The 2015 Pregnancy and Lactation Labeling Rule replaced the old letter grades (A, B, C, D, X) with narrative risk summaries. FDA guidance on the PLLR requires manufacturers to describe human and animal data separately, include a clinical considerations section, and provide lactation data, a materially more useful format than a single letter.

The Risk-Benefit Equation Is Never One-Sided

Refusing to prescribe carries its own fetal risk. A 2019 systematic review in JAMA Psychiatry (N=29 cohort studies) found that untreated depression during pregnancy was independently associated with preterm birth (OR 1.37, 95% CI 1.18 to 1.60) and low birth weight. Cite: JAMA Psychiatry 2019. The same principle applies to uncontrolled hypertension, unmanaged gestational diabetes, and undertreated hypothyroidism.

How Teratogenic Risk Is Actually Classified

The TERIS database and Reprotox remain the two most-cited expert systems for fetal risk grading beyond FDA labeling. TERIS at NIH rates drugs on a six-point scale from "none" to "high" based on the totality of human and animal evidence. The presence of any animal toxicity does NOT automatically mean a drug is dangerous in clinical doses in humans, a distinction clinicians must explain clearly to patients.

Gestational Diabetes: Medications That Work

Gestational diabetes mellitus (GDM) affects 6 to 9% of pregnancies in the United States per CDC estimates, and CDC surveillance data shows the prevalence has risen 56% over the last two decades. Medical nutrition therapy is always the starting point, but approximately 30 to 40% of patients will need pharmacologic intervention to reach glycemic targets of fasting glucose <95 mg/dL and 1-hour postprandial <140 mg/dL.

Insulin: The Reference Standard

Insulin does not cross the placenta at therapeutic doses and has the longest safety record of any GDM agent. ACOG Practice Bulletin 190 designates insulin as the preferred agent when pharmacotherapy is needed. NPH insulin and regular insulin have the most strong safety data; insulin aspart and insulin lispro also carry acceptable profiles based on pharmacokinetic studies at NIH.

Starting dose is typically 0.7 to 1.0 units/kg/day in divided doses in the second trimester, rising to 0.9 to 1.2 units/kg/day in the third trimester due to increasing insulin resistance.

Metformin in GDM

The MiG Trial (N=751) published in the New England Journal of Medicine compared metformin to insulin in GDM. MiG Trial, NEJM 2008 showed metformin was not inferior for the primary composite neonatal outcome (32.0% vs. 32.2%), and 46.3% of metformin patients required supplemental insulin. Metformin does cross the placenta; long-term follow-up data to age 9 showed no significant difference in body composition between children exposed to metformin versus insulin, per a 2018 report. Metformin follow-up, PubMed.

Why Glyburide Was Removed From First-Line Recommendations

A 2015 meta-analysis in Obstetrics and Gynecology (N=6,139 across 15 RCTs) found glyburide was associated with higher rates of neonatal hypoglycemia (RR 2.62) and macrosomia (RR 1.97) versus insulin. PubMed citation. ACOG Practice Bulletin 190 accordingly removed glyburide from its list of preferred agents.

Hypertension in Pregnancy: Three Agents, Clear Hierarchy

Chronic hypertension complicates 1 to 5% of pregnancies and carries a 25% risk of superimposed preeclampsia. ACOG Practice Bulletin 203 and the landmark CHIPS Trial (Control of Hypertension in Pregnancy Study, N=987) inform current treatment targets.

Labetalol

Labetalol, a combined alpha-beta blocker, is the most commonly prescribed oral antihypertensive in pregnancy in the United States. The CHIPS Trial, published in NEJM 2015, found that targeting diastolic blood pressure of 85 mmHg versus 100 mmHg reduced severe hypertension without increasing pregnancy loss or high-level neonatal care. Labetalol was the most frequently used study drug. Typical starting dose: 100 mg twice daily, titrated to 2,400 mg/day maximum.

Nifedipine Extended-Release

Nifedipine ER (30 to 120 mg/day) is the preferred calcium channel blocker. A Cochrane review of 49 trials confirmed it effectively lowers blood pressure with an acceptable fetal profile. Cochrane antihypertensives in pregnancy. Immediate-release nifedipine is avoided because rapid BP drops can compromise uteroplacental blood flow.

Methyldopa and What to Avoid

Methyldopa (250 to 3,000 mg/day) has the longest safety record of any antihypertensive in pregnancy, with follow-up data extending to 7 years postpartum, but its sedation burden makes it a second choice for most patients. ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated after the first trimester due to fetal renal dysgenesis and oligohydramnios. FDA drug safety communication.

Thyroid Disease in Pregnancy: Levothyroxine Dose Adjustments Are Mandatory

Hypothyroidism affects roughly 0.3 to 0.5% of pregnancies in overt form and up to 2 to 3% subclinically. Endocrine Society Clinical Practice Guideline 2017 sets the TSH treatment target at 0.2 to 2.5 mIU/L in the first trimester.

Why the Dose Must Rise Immediately

Levothyroxine requirements increase by 25 to 50% during the first 8 weeks of pregnancy in women with pre-existing hypothyroidism. A 2004 NEJM study demonstrated that inadequately treated hypothyroidism in early pregnancy was associated with impaired neurodevelopment in offspring, with IQ scores averaging 4 points lower in children of untreated women. The practical implication is that known hypothyroid patients should increase their levothyroxine dose by two tablets per week (a 28% increase) as soon as pregnancy is confirmed, then recheck TSH within 4 weeks. Endocrine Society guidance.

Graves Disease and Antithyroid Drugs

For hyperthyroidism, propylthiouracil (PTU) is preferred in the first trimester because methimazole carries a small but documented risk of embryopathy including choanal atresia. FDA drug safety communication on methimazole. After week 16, many clinicians switch to methimazole to reduce the risk of PTU-associated liver toxicity. Both drugs cross the placenta and can suppress fetal thyroid function; the lowest effective dose controls the fetus's risk.

Depression and Anxiety: Balancing Fetal Exposure Against Maternal Illness

Perinatal depression affects 10 to 15% of pregnant people, with higher rates in those with prior depressive episodes or low social support. ACOG Committee Opinion 757 recommends universal depression screening at least once per trimester using the Edinburgh Postnatal Depression Scale.

SSRIs: The First-Line Evidence Base

Sertraline and escitalopram have the most extensive safety data among SSRIs in pregnancy. Sertraline is most frequently cited as first-line based on the largest body of observational evidence. A 2013 cohort study in BMJ (N=845,345 pregnancies) found no significant increase in major congenital malformations with first-trimester SSRI exposure after controlling for confounders. BMJ 2013 SSRI cohort.

Paroxetine carries the most caution; FDA safety advisory on paroxetine notes a potential association with cardiac septal defects, though absolute risk remains small (prevalence increase from approximately 1% to 2%).

Persistent Pulmonary Hypertension of the Newborn (PPHN) Risk

SSRI use after week 20 has been associated with PPHN. The absolute risk is approximately 3 per 1,000 exposed newborns versus 1 to 2 per 1,000 unexposed, per a 2012 BMJ meta-analysis. Neonatal adaptation syndrome (jitteriness, feeding difficulty) occurs in 15 to 30% of neonates exposed to SSRIs near delivery and is self-limiting within 2 weeks. Clinical guidance from the British Association for Psychopharmacology recommends continuing effective antidepressants through delivery rather than tapering, because relapse risk in the postpartum period outweighs neonatal adaptation risk in most patients.

SNRIs, Bupropion, and Benzodiazepines

Venlafaxine and duloxetine have less gestational safety data than sertraline but are used when SSRIs alone are ineffective. Bupropion is generally avoided in the first trimester due to a possible cardiovascular signal, though evidence remains mixed. PubMed bupropion pregnancy review. Benzodiazepines should be limited to short-course rescue use; chronic use is associated with neonatal withdrawal and preterm birth in observational data.

Opioid Use Disorder in Pregnancy: Medication-Assisted Treatment Is Non-Negotiable

Abrupt opioid discontinuation in pregnancy carries documented risk of miscarriage, preterm labor, and fetal distress. ACOG Committee Opinion 711 states clearly: "Medically supervised withdrawal is associated with high relapse rates and is not recommended." The two standard-of-care medications are buprenorphine and methadone.

Buprenorphine

Buprenorphine (sublingual, 4 to 24 mg/day) is increasingly preferred over methadone in outpatient settings because it can be prescribed in office-based settings under the DATA 2000 framework. The MOTHER Trial (N=131) published in NEJM compared buprenorphine to methadone for neonatal outcomes. MOTHER Trial, NEJM 2010 found neonatal abstinence syndrome (NAS) was significantly less severe with buprenorphine: morphine required for NAS was 89% less (1.1 mg vs. 10.4 mg), and hospital stay was 43% shorter (10.0 vs. 17.5 days).

Methadone

Methadone (clinic-based dosing, typically 80 to 120 mg/day) remains the standard for patients who cannot achieve stability on buprenorphine or who need the structure of daily observed dosing. Both agents cause NAS; NAS is treatable and does not represent a reason to withhold medication-assisted treatment from the mother. Substance Abuse and Mental Health Services Administration treatment improvement protocol provides the clinical framework most U.S. Programs use.

GLP-1 Receptor Agonists and Pregnancy: Current Guidance

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are increasingly prescribed for type 2 diabetes and obesity, making pregnancy exposure an emerging clinical scenario. FDA labeling for semaglutide and animal reproductive toxicology studies show dose-related fetal structural abnormalities including reduced fetal weight and skeletal malformations at exposures comparable to the human therapeutic range.

The practical clinical framework used by the HealthRX medical team follows a three-phase approach: (1) discontinue semaglutide or liraglutide at least 2 months before planned conception (the drug's 5-week half-life means meaningful fetal exposure can persist well past the last dose); (2) transition to insulin if glycemic control is needed during pregnancy; (3) resume GLP-1 therapy postpartum only after breastfeeding is discontinued, given the absence of human lactation safety data. Tirzepatide (Mounjaro, Zepbound) carries the same precautions per FDA Mounjaro labeling.

No human RCT data exist on GLP-1 agonists in pregnancy, and the available animal data are sufficient to recommend avoidance. A 2023 narrative review in Diabetes Care reached the same conclusion, recommending that all patients of reproductive age on GLP-1 agonists receive explicit contraceptive counseling.

Medications to Avoid in Pregnancy: A Reference List

Not every contraindication is absolute, but the following carry the strongest evidence for fetal harm and should be avoided unless no safer alternative exists.

| Drug / Class | Primary Risk | Evidence Grade | |---|---|---| | ACE inhibitors / ARBs (T2, T3) | Fetal renal dysgenesis, oligohydramnios | Human RCT / registry data | | Isotretinoin | Severe craniofacial, cardiac, CNS defects (30% risk) | Multiple human cohorts | | Valproate | Neural tube defects (1 to 2%), IQ reduction (avg. 8 pts) | Neurodevelopmental outcome studies | | Warfarin (T1) | Embryopathy (5 to 10%), CNS defects | Registry data | | Tetracyclines (T2, T3) | Tooth discoloration, inhibited bone growth | Animal and human data | | Fluoroquinolones | Possible cartilage toxicity (animal data; human risk unclear) | Animal studies, limited human data | | Thalidomide | Limb reduction defects (phocomelia) | Historical cohort | | Methimazole (T1) | Aplasia cutis, choanal atresia | Case series and registry | | Misoprostol (high dose) | Uterine rupture, Mobius sequence | Case reports and registry |

Sources: ACOG Teratology guidelines, MotherToBaby fact sheets via NIH, FDA drug label database.

Folic Acid and Prenatal Vitamins: The One Intervention With Near-Universal Consensus

The CDC recommends 400 to 800 mcg of folic acid daily for all people who could become pregnant. CDC folic acid guidance estimates that adequate periconceptional folic acid reduces neural tube defect (NTD) risk by 50 to 70%. The U.S. Preventive Services Task Force gives this an "A" grade recommendation. USPSTF folic acid recommendation.

Patients with a prior NTD-affected pregnancy, on valproate, or with MTHFR homozygous variant need 4 mg/day, started at least 1 month before conception. Standard prenatal vitamins contain 800 to 1,000 mcg and cover most patients, but patients on valproate require a separate high-dose folic acid prescription rather than relying on prenatal vitamins alone. NIH Office of Dietary Supplements folic acid fact sheet.

Monitoring Protocols Across Trimesters

Most prescription changes in pregnancy require reassessment every 4 weeks rather than every trimester. The table below summarizes minimum monitoring intervals for the most commonly managed conditions.

| Condition / Drug | Monitoring Parameter | Interval | |---|---|---| | Hypothyroidism / levothyroxine | TSH | Every 4 weeks T1, every 4 to 6 weeks T2/T3 | | GDM / insulin | Fasting and postprandial glucose | Daily self-monitoring | | GDM / metformin | Fasting glucose, HbA1c | Every 4 to 6 weeks | | Chronic HTN / labetalol | BP, fetal growth | Every 2 to 4 weeks | | OUD / buprenorphine | Drug screen, NAS assessment neonatal | Every 2 to 4 weeks maternal; neonatal 3 to 7 days | | Depression / SSRI | Edinburgh score, neonatal adaptation review | Every 4 weeks | | Epilepsy / valproate | Drug levels, AFP, anatomy scan | Levels monthly; anatomy scan at 18 to 20 weeks |

Endocrine Society monitoring guidance and ACOG Practice Bulletin 203 form the primary basis for these intervals.

When to Refer to Maternal-Fetal Medicine

Primary care and OB-GYN providers manage the majority of medication decisions in pregnancy. Referral to maternal-fetal medicine (MFM) is appropriate when a patient takes a known teratogen (valproate, lithium, warfarin) and cannot be safely transitioned; when a condition requires agents with narrow therapeutic indices (e.g., antiepileptic polypharmacy); or when the patient has a prior adverse pregnancy outcome potentially related to medication exposure. The Society for Maternal-Fetal Medicine recommends MFM consultation for any patient on chronic opioid therapy who becomes pregnant. SMFM consult series on OUD.

Complex cases involving psychiatric medications at high doses should include a perinatal psychiatrist. The Reproductive Psychiatry Resource and Information Center at MGH provides prescriber-level decision tools referenced in a JAMA Psychiatry practice guidance.